Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.71 |
| ▸ | KDR | P35968 | 14/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15492448 | 0.84 | ATM (0.64) | METKDRATMPIM1BIRC5 | |
| SCHEMBL2819537 | 0.81 | KDR (0.46) | METKDRATMPIM1BIRC5 | |
| SCHEMBL2200660 | 0.79 | ATM (0.51) | METKDRATMPIM1BIRC5 | |
| SCHEMBL2199412 | 0.78 | KDM4E (0.54) | METKDRATMPIM1BIRC5 | |
| SCHEMBL2198100 | 0.78 | GLA (0.54) | METKDRATMPIM1BIRC5 | |
| SCHEMBL2201233 | 0.75 | GSTP1 (0.51) | METKDRATMPIM1 | |
| SCHEMBL2199168 | 0.74 | KDM4E (0.55) | METKDRATMPIM1BIRC5 | |
| SCHEMBL2202978 | 0.74 | PIM1 (0.50) | ATMPIM1BIRC5 | |
| SCHEMBL2203894 | 0.73 | KDR (0.53) | METKDRATMPIM1BIRC5 | |
| SCHEMBL2201226 | 0.72 | KDM4E (0.50) | ATMPIM1BIRC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| EP-1841767-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | Bayer Schering Pharma AG (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20060252754-A1 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2006077168-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | BAYER SCHERING PHARMA AG. (DE) | 2006-07-27 | — | — | WO | disclosed |
| EP-1683796-A1 | Pyrazolopyridines, their preparation and their medical use | Schering Aktiengesellschaft (DE) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252754-A1 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | TEK, TIE1, KDR | MET 1371/4885KDR 3/4885MAPK14 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.